A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-24

Study Completion Date

2021-07-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults. Twenty-eight healthy adult subjects will be enrolled into the study to receive a single dose of COVID-HIGIV or placebo with 84 days of safety and PK follow-up post-administration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

NCT04469179

COVID-19 SARS-CoV2

UNKNOWN PHASE1

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

NCT04679350

COVID-19

TERMINATED PHASE2

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

NCT04632381

Corona Virus Infection

COMPLETED PHASE1

Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients

NCT04793984

Covid19

COMPLETED NA

Zofin (Organicell Flow) for Patients With COVID-19

NCT04384445

Corona Virus Infection COVID-19 SARS +1 more

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a Phase 1, single-center, randomized, double-blind, placebo-controlled design to assess safety and PK of COVID-HIGIV in healthy adults.

In total, 28 healthy adult subjects are to be enrolled and randomized 2:2:2:1 into four study treatment arms to receive a single intravenous (IV) infusion of one of three COVID-HIGIV dose levels or saline placebo, respectively.

The enrollment/dosing of the first seven subjects in the study will be staggered. Available safety data will be reviewed by Study Monitoring Committee (SMC) after seven subjects have completed at least 72 hours of safety follow-up. Subjects will be followed up for safety and PK up to 84 days post-administration.

The SMC will perform overall ongoing review of safety data during the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID-HIGIV Dose Level 1 (100 mg/kg)

Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 1 (100 mg/kg).

Group Type EXPERIMENTAL

COVID-HIGIV

Intervention Type BIOLOGICAL

COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.

COVID-HIGIV Dose Level 2 (200 mg/kg)

Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 2 (200 mg/kg).

Group Type EXPERIMENTAL

COVID-HIGIV

Intervention Type BIOLOGICAL

COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.

COVID-HIGIV Dose Level 3 (400 mg/kg)

Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 3 (400 mg/kg).

Group Type EXPERIMENTAL

COVID-HIGIV

Intervention Type BIOLOGICAL

COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.

Dose Placebo (saline)

Eligible subjects randomized to receive a single IV infusion of saline placebo.

Group Type PLACEBO_COMPARATOR

Placebo (saline)

Intervention Type OTHER

The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-HIGIV

COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.

Intervention Type BIOLOGICAL

Placebo (saline)

The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NP-028

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able and willing to provide written informed consent (voluntarily signed by the subject) prior to performing study procedures.
2. Females and males 18-60 years of age, inclusive.
3. Have a body mass index (BMI) less than or equal to 35.0 kg/m2.
4. Women who are either:

A) Not of childbearing potential: either surgically sterile (at least six weeks post bilateral tubal ligation, bilateral oophorectomy or hysterectomy); or post-menopausal (defined as ≥50 years of age with a history of ≥12 months without menses prior to randomization in the absence of other pathologic or physiologic causes, following cessation of exogenous sex-hormonal treatment); OR

B) Women of childbearing potential (WOCBP) who are not planning to be pregnant during the study period and meet all of the following criteria:

Negative serum pregnancy test (PT) at Screening; and Negative PT prior to dosing at Day 1; and

Use of a highly effective contraception during the study period:
* Hormonal contraceptives (e.g., implants, pills, patches) initiated ≥30 days prior to Day 1; or
* Intrauterine device (IUD) inserted ≥30 days prior to Day 1; or
* Double barrier type of birth control (e.g., male condom with female diaphragm, male condom with cervical cap).
5. Subject understands and agrees to comply with planned study procedures.
6. Healthy as determined by the Principal Investigator based on medical history, physical exam, vital signs, urinalysis, blood chemistry and hematology test results at Screening and evidence of no prior exposure to SARS-CoV-2 (i.e., Reverse transcription polymerase chain reaction \[RT-PCR\] negative for SARS-CoV-2 and negative for SARS-CoV-2 antibodies) at Screening.

Exclusion Criteria

1. Use of any investigational product, within 30 days prior to Screening, or use of investigational SARS-CoV-2 vaccines, SARS-CoV-2 monoclonal antibodies or COVID-19 convalescent plasma at any time prior to Screening or during the study follow-up period, or subject plans to participate in another clinical study during the study period.
2. Screening clinical laboratory test result greater than the laboratory's upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), random glucose, total and/or bilirubin, blood urea nitrogen (BUN), or creatinine. Other serum chemistry parameters that are not within the reference range will not be considered exclusionary unless deemed clinically significant by the Principal Investigator.
3. History of allergy or hypersensitivity to blood or plasma products or to COVID-HIGIV excipients (proline, PS80).
4. History of allergy to latex or rubber.
5. History of hemolytic anemia.
6. History of Immunoglobulin A (IgA) deficiency.
7. Receipt of any blood product within the past 12 months.
8. Plasma donation within 7 days or significant blood loss or blood donation within 56 days of randomization/dosing.
9. History of known congenital or acquired immunodeficiency or receipt of immunosuppressive therapy (e.g., prednisone or equivalent for more than two consecutive weeks within the past three months).
10. History of thrombosis or hypercoagulable state with increased risk of thrombosis.
11. History of clinically significant chronic illness (e.g., requiring hospitalization in the past three months) such as cardiac, pulmonary, renal, hepatic or other chronic conditions.
12. Receipt of a live vaccine within 28 days prior to screening or anticipated receipt of a live vaccine during the study period.
13. Currently pregnant, breastfeeding, or planning to become pregnant during the study.
14. History of, or suspected substance abuse problem (including alcohol).
15. Other medical condition which may place subject at increased risk due to participation in the study as determined by the investigator.
16. Any planned elective surgery during the study period.
17. An opinion of the investigator that it would be unwise to allow the individual to be randomized into the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes